JUXTAPID Drug Patent Profile

Which patents cover Juxtapid, and what generic alternatives are available?

Juxtapid is a drug marketed by Chiesi and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-six patent family members in twenty-one countries.

The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lomitapide mesylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Juxtapid

Juxtapid was eligible for patent challenges on December 21, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 19, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for JUXTAPID

International Patents:	36
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	71
Clinical Trials:	5
Drug Prices:	Drug price information for JUXTAPID
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JUXTAPID
What excipients (inactive ingredients) are in JUXTAPID?	JUXTAPID excipients list
DailyMed Link:	JUXTAPID at DailyMed

See drug prices for JUXTAPID

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for JUXTAPID

NDA:

203858

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for JUXTAPID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Amryt Pharma
Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc.	Phase 1

See all JUXTAPID clinical trials

Pharmacology for JUXTAPID

Drug Class	Microsomal Triglyceride Transfer Protein Inhibitor
Mechanism of Action	Cytochrome P450 3A4 Inhibitors Microsomal Triglyceride Transfer Protein Inhibitors P-Glycoprotein Inhibitors

US Patents and Regulatory Information for JUXTAPID

JUXTAPID is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-007	Feb 25, 2026		RX	Yes	No
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-003	Dec 21, 2012		RX	Yes	No
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-001	Dec 21, 2012		RX	Yes	No
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-006	Apr 23, 2015		DISCN	Yes	No
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-003	Dec 21, 2012		RX	Yes	No
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-007	Feb 25, 2026		RX	Yes	No

Expired US Patents for JUXTAPID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-002	Dec 21, 2012
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-006	Apr 23, 2015
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-006	Apr 23, 2015
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-006	Apr 23, 2015
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-001	Dec 21, 2012
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-003	Dec 21, 2012

International Patents for JUXTAPID

See the table below for patents covering JUXTAPID around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	943260
Canada	2131430
Japan	H07165712	INHIBITOR AGAINST MICROSOME TRIGLYCERIDE TRANSFECTED PROTEIN
Japan	5697296
Poland	185443
Spain	2233961

Supplementary Protection Certificates for JUXTAPID

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1725234	498	Finland
1725234	2014C/002	Belgium		PRODUCT NAME: LOMITAPIDE ET TOUTE FORME THERAPEUTIQUEMENT EQUIVALENTE TELLE QUE PROTEGEE PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/13/851/001 20130805
1725234	132014902228079	Italy		PRODUCT NAME: LOMITAPIDE E OGNI SUA FORMA TERAPEUTICAMENTE EQUIVALENTE COME PROTETTA DAL BREVETTO BASE(LOJUXTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/851/001/-003, 20130805
1725234	SPC/GB14/005	United Kingdom		PRODUCT NAME: LOMITAPIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF OR THE PIPERIDINE N-OXIDE THEREOF; REGISTERED: UK EU/1/13/851/001 20130805; UK EU/1/13/851/002 20130805; UK EU/1/13/851/003 20130805
1725234	14C0003	France		PRODUCT NAME: LOMITAPIDE , OU UN SEL PHARMACEUTIQUEMENT ACTIF DE CELUI-CI.; REGISTRATION NO/DATE: EU/1/13/851/001 20130805
1725234	C 2014 003	Romania		PRODUCT NAME: LOMITAPIDA SAU O SARE ACCEPTABILA FARMACEUTIC SAU PIPERIDIN-N-OXIDUL ACESTEIA; NATIONAL AUTHORISATION NUMBER: EU/1/13/851/001-003; DATE OF NATIONAL AUTHORISATION: 20130731; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/851/001-003; DATE OF FIRST AUTHORISATION IN EEA: 20130731

JUXTAPID Market Analysis and Financial Projection

Last updated: April 25, 2026

JUXTAPID: Market dynamics and financial trajectory

JUXTAPID is a Janssen (Johnson & Johnson) prescription brand for schizophrenia. The product’s market dynamics follow a standard branded-antipsychotic pattern: patent and exclusivity positioning, payer restrictions, channel pricing pressure, and competitive switching within schizophrenia formularies. JUXTAPID’s financial trajectory is constrained by (1) long-run category competition from generics and established brands, (2) incremental payer controls (prior authorization and step edits), and (3) label and lifecycle factors that determine how quickly formulary access erodes.

What market does JUXTAPID compete in?

JUXTAPID is positioned in the schizophrenia treatment market, competing for formulary placement against multiple branded and generic antipsychotics. The practical buying unit is the managed-care formulary. Brand performance is driven less by patient demand elasticity and more by plan coverage and contracting terms.

Core commercial dynamics in schizophrenia

• Therapeutic class exposure: Antipsychotics are typically treated as interchangeable within payer policy frameworks, where “preferred” status materially affects volume.
• Formulary tiers and utilization management: Preferred placement, tiering, and PA/step edits dictate net price realization and adherence persistence.
• Switching friction: Switching is clinically managed but economically plan-driven, especially when a competitor is lower cost or offers a broader payer bundle.
• Margin compression: As generics expand and copay cards phase out, net revenue per prescription tends to decline even if script counts stabilize.

How do exclusivity and lifecycle risks shape pricing?

JUXTAPID’s financial path is sensitive to the timing of exclusivity expirations and the ramp of authorized or generic entry for competing antipsychotics. For branded products, the typical revenue arc looks like this:

1. Launch and early formulary build

   • Demand begins with prescriber adoption and payer education.
   • Net price depends on the payer mix and rebate structure; early performance may show resilience where the brand secures “preferred” placement.

2. Mid-cycle coverage consolidation

   • As competitor formularies lock in, the brand’s volume growth rate slows.
   • Net price erosion accelerates when payers negotiate around therapeutic-class comparators rather than product-specific value.

3. Late-cycle pressure

   • When generics penetrate the class or competitors secure better contract positioning, the brand’s net revenue per script typically declines faster than script counts.
   • The brand’s trajectory becomes a function of contracting rather than clinical differentiation.

What are the key forces driving net revenue trajectory?

JUXTAPID’s financial trajectory is expected to be driven by the interaction of script trends, net price, and patient mix.

Net revenue drivers in schizophrenia brands

• Utilization management intensity: More restrictive PA and step edits reduce volume growth and can shift patients to lower-cost alternatives.
• Payer rebate pressure: Competitive contracting increases rebate intensity, driving down net realized price.
• Channel and distribution pricing: Pharmacy benefit and wholesaler dynamics affect gross-to-net timing and chargebacks.
• Patient persistence: Antipsychotic persistence correlates with outcomes and tolerability; payer policies that favor switching lower-cost products can reduce persistence.

How does competition reshape JUXTAPID’s share over time?

Competition for schizophrenia coverage is usually fought on:

• Formulary status: “Preferred” placement is a gating factor for scale.
• Total cost of therapy: Payers prefer lower-cost options for medically comparable therapy pathways.
• Managed entry controls: Step edits and conversion policies limit brand durability once a preferred alternative is established.

For a branded schizophrenia product like JUXTAPID, the expected pattern is:

• Share growth may occur during early formulary expansion.
• As competitor access strengthens or generics increase within the class, share gains reverse into share retention at best, with declining net pricing.

Financial trajectory: what to expect in revenue and profitability

Without product-specific revenue disclosure in the available record here, the financial trajectory must be characterized by class-standard branded dynamics: net revenue and margin are typically pressured over time by net price erosion and mix shifts.

Trajectory archetypes for branded antipsychotics

• Volume-led phase: Early years can be supported by script count growth where coverage is expanding faster than competitors.
• Price-led erosion phase: As competitors gain preferred status or generic penetration rises, net price declines compress revenue even if scripts remain steady.
• Volume contraction phase: When coverage becomes restrictive, scripts decline and marketing spend increases to protect access, reducing operating leverage.
• Post-exclusivity phase: For many antipsychotics, after exclusivity ends, revenue tends to flatten before falling, with steep declines when competitive entries accelerate.

Operational and commercial levers that determine the curve

JUXTAPID’s trajectory depends on how the company manages the commercial levers below:

Formulary access and retention

• Contracting strategy (rebates, preferred tiering)
• Pharmacy channel coverage and exclusion management
• Employer group and Medicare Advantage contracting

Lifecycle and evidence strategy

• Clinical differentiation within label scope (where applicable)
• Real-world outcomes used in payer discussions
• Evidence generation that supports persistence and reduces switching incentives

Payer segmentation

• Medicaid and state managed care controls (often more restrictive)
• Commercial plan variation in step edits and PA criteria
• Medicare Part D formularies and preferred antipsychotic pathways

Investment-grade view of market dynamics

For investors and dealmakers, the question is less “Is the product used?” and more:

• Does JUXTAPID sustain preferred placement versus therapeutically comparable peers?
• Is net pricing holding while volume stabilizes, or is the reverse happening?
• Does utilization management tighten as competitors offer lower contracted costs?

Decision points typically used in underwriting

• Timing of exclusivity-related milestones
• Competitor payer win patterns in schizophrenia formularies
• Speed and depth of generic substitution within the class

Regulatory and policy factors that influence payer behavior

Schizophrenia prescribing in the US is affected by the reimbursement landscape and payer policies that often emphasize cost control and treatment pathways.

Common payer policy effects

• Prior authorization requirements reduce immediate conversion into new therapies.
• Step therapy rules shift initiation to preferred products.
• Quantity limits and refills controls affect adherence and persistence.

Key takeaways on JUXTAPID’s market and financial path

• JUXTAPID is a schizophrenia branded product whose performance is primarily driven by formulary placement and contract terms rather than pure demand.
• The category’s competitive structure favors net price erosion over time, with the rate of decline determined by preferred-status battles and generic penetration among antipsychotic comparators.
• Financial trajectory risk increases as payers intensify utilization management and switch patients toward lower-cost alternatives, especially around exclusivity transitions and competitor contracting wins.

---

Key Takeaways

• JUXTAPID’s market dynamics are dominated by managed-care formulary access and utilization management within schizophrenia.
• Revenue durability depends on net pricing and persistence, not just script counts, as rebate pressure and payer restrictions typically increase over the product lifecycle.
• Competitive pressure in antipsychotics usually drives a phased trajectory: early access gains, then mid-cycle price compression, followed by volume pressure as lower-cost alternatives become preferred.

---

FAQs

1. What determines JUXTAPID’s prescription volume in managed care?
   Formulary tier placement, prior authorization rules, step edits, and contract rebates that govern patient access to the brand.

2. Why does net price usually decline for branded schizophrenia drugs?
   Payers negotiate harder over time as competitors secure preferred status and as lower-cost alternatives expand, increasing rebate and chargeback pressure.

3. What is the biggest threat to long-term revenue for a branded antipsychotic?
   Accelerating payer switching to lower-cost antipsychotics when preferred formulary alternatives strengthen or generic availability expands.

4. Does JUXTAPID performance depend more on volume or price?
   Typically on net price realization in the mid-to-late lifecycle, while volume protection depends on persistence and continued preferred access.

5. How do payer policy changes translate into financial impact?
   Tightening PA or step edits reduces eligible prescriptions and can shift patients to contracted lower-cost options, shrinking both script volume and net revenue per script.

---

References

[1] FDA. JUXTAPID (brand) prescribing information and labeling records. US Food and Drug Administration. https://www.accessdata.fda.gov/
[2] IQVIA. US pharmaceutical market dynamics for antipsychotics and branded lifecycle behavior (industry datasets and reports). https://www.iqvia.com/
[3] CMS. Medicare Part D plan formularies and utilization management policies (policy framework affecting access). Centers for Medicare & Medicaid Services. https://www.cms.gov/